Defendant
1 case as defendant.
Tempus AI, Inc. (formerly Tempus Labs) is a health technology company headquartered in Chicago, Illinois, founded in 2015 by Eric Lefkofsky. The company went public on the Nasdaq on June 14, 2024, trading under the ticker symbol "TEM". As of May 2026, Tempus AI has approximately 3,800 employees and a trailing 12-month revenue of $1.36 billion, with a market capitalization of $8.24 billion.
Tempus AI specializes in AI-enabled precision medicine, leveraging data and artificial intelligence to enhance healthcare. Its offerings are organized into three primary product lines: Genomics, Data and Services, and AI Applications. The Genomics line includes diagnostics, PCR profiling, and other molecular pathology tests for healthcare providers and life sciences companies. The Data and Services line involves licensing de-identified patient data for drug development, AI-enabled clinical trial matching, and analytical services. AI Applications encompass tools such as a generative AI clinical assistant, a multimodal real-world data analytics platform, digital pathology imaging, and pharmacogenomic testing, focusing on areas like oncology, neuropsychiatry, cardiology, and radiology.
In terms of patent litigation, Tempus AI Inc. appears to be an active litigant involved in disputes with direct competitors. The company has a balanced litigation posture with one case as a plaintiff and one as a defendant. Both tracked cases involve Guardant Health Inc., another precision oncology company specializing in cancer testing. This suggests a two-way dispute between industry players rather than an assertion campaign by a Non-Practicing Entity (NPE).
The notable cases include Tempus AI Inc. v. Guardant Health Inc. at the Patent Trial and Appeal Board (PTAB), initiated on 2025-08-15, where Tempus AI is the plaintiff. Conversely, Tempus AI Inc. is a defendant in Guardant Health, Inc. v. Tempus AI, Inc., filed on 2024-06-11 in the U.S. District Court for the District of Delaware. The involvement of both companies in these cases indicates a direct competitive intellectual property dispute.
Guardant Health, Inc. filed a patent infringement suit against Tempus AI, Inc., alleging infringement of US10793916 and other patents, seeking an injunction and compensatory damages. The case is active, with a Markman Hearing reset for October 20, 2026, and a jury trial reset for October 23, 2028.